PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
646 episodes - English - Latest episode: 10 days ago - ★★★★ - 8 ratingsPeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Richard S. Finn, MD / Laura M. Kulik, MD - Rethinking Care in Hepatocellular Carcinoma Amid Expanding Treatment Options: An Interdisciplinary Discussion
May 24, 2019 23:00 - 58 minutesGo online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on stra...
John C. Byrd, MD - BTK Inhibition as an Anti-Cancer Strategy: Exploring a Model for Modern Targeted Therapy in Hematologic Malignancies and Beyond
May 22, 2019 23:00 - 1 hourGo online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologi...
Robert Anders, MD, PhD - Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Implications for Pathologists at the Forefront of the Emerging Precision Immuno-Oncology Era
May 20, 2019 23:00 - 1 hourGo online to PeerView.com/FJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of solid tumors and hematologic malignancies. Reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit. Testing for programmed death-ligand 1 (PD-L1) expression and th...
Scott J. Antonia, MD, PhD - Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy: Cutting-Edge Research, Clinical Applications, and Practical Challenges
May 17, 2019 23:00 - 59 minutesIn this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing an...
Amy Goodrich, NP - Oncology Nurse Insights Into New Agent Classes and Research in B-Cell Lymphoma: Practical Issues and Evidence for the Front-Lines of Care
May 15, 2019 23:00 - 34 minutesGo online to PeerView.com/JHB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology-oncology nurse expert reviews the latest evidence on novel agent classes and ongoing research in B-cell lymphoma and offers insights on practical issues that nurses caring for patients with B-cell malignancies face in routine practice. Upon completion of this activity, participants will be able to: Review updated efficacy ...
Justin F. Gainor, MD - New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine and Expand the Use of Cancer Immunotherapies and Combinations
May 09, 2019 23:00 - 1 hourGo online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno...
Jason J. Luke, MD, FACP and Jennifer Wargo, MD, MMSc - Progress and Promise With Immunotherapy in Resectable Melanoma: Exploring New Evidence and Practical Issues With Checkpoint Inhibitors as Adjuvant Therapy
May 06, 2019 23:00 - 55 minutesGo online to PeerView.com/EWW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Melanoma was the first clinical setting in which the use of immune checkpoint inhibitors was validated, leading to their rapid integration into the management of advanced disease. More recently, checkpoint inhibitors, based on phase 3 evidence, have claimed a role in the adjuvant setting. The future of adjuvant therapy for high-risk resectable melanoma ...
Benjamin Levy, MD - Refining Current Practice and Exploring New Frontiers in EGFR-Mutant NSCLC: Evolving Science, New Standards of Care, and Implications for Multidisciplinary Management
May 03, 2019 23:00 - 1 hourGo online to PeerView.com/CXH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The best practices for management of patients with EGFR-mutant NSCLC continue to evolve as a result of advances in molecular testing and targeted treatment. Understanding what, when, and how to test, as well as how to select therapy, throughout the continuum of advanced NSCLC is paramount. In this activity, based on a recent live symposium held in San D...
Sagar Lonial, MD, FACP - Innovative Therapeutic Concepts for ASCT-Eligible Patients With Myeloma: Advancing Toward More Effective Care Across Treatment Settings
April 22, 2019 23:00 - 54 minutesGo online to PeerView.com/QAJ860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in myeloma offer guidance on the selection and sequencing of innovative therapies for the ASCT-eligible patients with multiple myeloma, and addre...
Mitchell S. Cairo, MD - Attacking the Clinical Problem of VOD/SOS in HCT Recipients: Insights on Pathophysiology, Diagnosis, and Treatment
April 17, 2019 23:00 - 52 minutesGo online to PeerView.com/SXH860 to view the entire program with slides. In this activity, based on a live symposium held during the 2019 Transplantation and Cellular Therapy (TCT) Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in hematology-oncology explore new developments related to the changing clinical consensus for managing veno-occlusive disease (VOD)/sinusoida...
Tanya Siddiqi, MD - Harnessing Recent Advances in CAR-T Cell Therapy for Leukemia and Lymphoma in the Era of Stem Cell Transplantation
April 15, 2019 23:00 - 52 minutesGo online to PeerView.com/ZGE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy (TCT) Meetings in Houston, Texas, experts in hematology and oncology explore the science behind adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells and discuss exciting new developments with this innovative approach as well as its clinical potential and role in managing relapsed/refractory hem...
Leonard H. Calabrese, DO - Rheumatology, Immunology, and Immuno-Oncology Intersect: Navigating the Complexities of Immune Checkpoint Inhibition, Autoimmunity, and Immune-Related Adverse Events: How Can Rheumatologists Help Minimize the Risks and Maximize the Benefits of Cancer Immunotherapies?
April 12, 2019 23:00 - 1 hourGo online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which...
Mark A. Socinski, MD - Expanding Options and Difficult Choices in the Initial Treatment of Advanced NSCLC: How to Personalize Treatment Decisions in the Era of Immuno-Oncology and Combinations
April 10, 2019 23:00 - 50 minutesGo online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for...
Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance
April 08, 2019 23:00 - 59 minutesGo online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating th...
Madan H. Jagasia, MBBS, MS, MMHC - Innovative Therapies in Post-Transplant GVHD: Personal Insights From the Patient CaseBook
April 05, 2019 23:00 - 48 minutesGo online to PeerView.com/XYM860 to view the entire program with slides. This activity utilizes a “CaseBook” format, offering learners a collection of patient case scenarios from the experts’ personal repertoire paired with analyses of how the treatment landscape in acute and chronic graft-versus-host disease (GVHD) is evolving. Hematology-oncology and bone marrow transplant professionals take a deep dive into the underlying immunology of GVHD and the latest evidence with innovative ...
Roy F. Chemaly, MD, MPH, FIDSA, FACP - Managing CMV in the New Era of Antiviral Therapy: Practical Considerations in the HCT Setting
April 03, 2019 23:00 - 49 minutesGo online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive the...
Robert Dreicer, MD, MS, MACP, FASCO - Unraveling the Complexities of Prostate Cancer Management: Focus on Therapeutic Decisions for Early-Stage Disease and the Implications for Later-Stage Disease
March 29, 2019 23:00 - 1 hourGo online to PeerView.com/XHP860 to view the entire program with slides. In this activity, experts in the management of patients with prostate cancer discuss recent advances that have rapidly expanded the therapeutic landscape, including treatments for both early-stage and advanced disease. Focusing on selection and sequencing of therapies based on patient and tumor characteristics, prior treatment history, and patient preferences, the expert panel provides an engaging MasterClass an...
David F. McDermott, MD - Making Effective Therapeutic Choices for Advanced RCC in an Evolving Treatment Landscape: Personal Insights From the Patient CaseBook
March 27, 2019 23:00 - 1 hourGo online to PeerView.com/FEJ860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Genitourinary Cancers Symposium in San Francisco, experts in renal cell carcinoma (RCC) dip into their patient “CaseBook” to offer insights from their own practice on how best to bridge the divide between clinical research and daily care in the management of RCC. Pairing analysis of the latest evidence with application of key clinical concepts t...
Luciano J. Costa, MD, PhD - Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact of Novel Platforms and Agent Classes Across the Spectrum of Care
March 20, 2019 23:00 - 32 minutesGo online to PeerView.com/WPW860 to view the entire program with slides. In this activity, an expert in multiple myeloma discusses newer safety and efficacy data surrounding novel and emerging therapeutic drug classes for multiple myeloma, including agents directed against intracellular targets and immune-based treatment. The activity will also include expert insights on how to develop effective, individualized treatment strategies with novel components that are informed by clinical ...
Nathan H. Fowler, MD - Building Innovative Treatment Options for Patients With B-Cell Malignancies: Practical Insights on Clinical Evidence and Integration Strategies
March 15, 2019 23:00 - 53 minutesGo online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews ...
Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED
March 11, 2019 23:00 - 32 minutesGo online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic...
Richard S. Finn, MD - Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes
March 08, 2019 23:00 - 1 hourBreaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes
Anna F. Farago, MD, PhD - The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to the Clinical Role of TRK Fusions in Personalizing Cancer Therapy
March 06, 2019 23:00 - 38 minutesThe TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to the Clinical Role of TRK Fusions in Personalizing Cancer Therapy
Guy Young, MD - Defining the Role of Extended Half-Life Replacement Clotting Factors in the Modern Management of Hemophilia A
March 01, 2019 23:00 - 38 minutesDefining the Role of Extended Half-Life Replacement Clotting Factors in the Modern Management of Hemophilia A
Edward S. Kim, MD, FACP - Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?
February 27, 2019 23:00 - 28 minutesBeyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?
Lynette M. Sholl, MD - Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and Updated Guidelines: What Pathologists Need to Know and Do
February 25, 2019 23:00 - 1 hourMolecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and Updated Guidelines: What Pathologists Need to Know and Do
Arjun Balar, MD - Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes
February 19, 2019 23:00 - 1 hourKeeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes
Anas Younes, MD - Progress in Developing Novel Treatment Options for PTCL: Expert Views on Integrating Innovative Therapeutics Into Care
February 15, 2019 23:00 - 21 minutesProgress in Developing Novel Treatment Options for PTCL: Expert Views on Integrating Innovative Therapeutics Into Care
Robert Anders, MD, PhD - The Central Role of Biomarker Testing in Piecing Together the Immuno-Oncology Puzzle: Essential Guidance for Pathologists to Maximize the Potential of Cancer Immunotherapies
February 13, 2019 23:00 - 1 hourThe Central Role of Biomarker Testing in Piecing Together the Immuno-Oncology Puzzle: Essential Guidance for Pathologists to Maximize the Potential of Cancer Immunotherapies
Naiyer Rizvi, MD - The Evolving Role of Immunotherapy as a Component of Multimodal Therapy in Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Multidisciplinary Care
February 07, 2019 23:00 - 41 minutesThe Evolving Role of Immunotherapy as a Component of Multimodal Therapy in Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Multidisciplinary Care
Michael B. Atkins, MD - Incorporating Cancer Immunotherapies Into the Oncology Treatment Arsenal in Managed Care Settings: Navigating the Complexities of Value Assessment & Cost Optimization in the Era of Immuno-Oncology
February 05, 2019 23:00 - 1 hourIncorporating Cancer Immunotherapies Into the Oncology Treatment Arsenal in Managed Care Settings: Navigating the Complexities of Value Assessment & Cost Optimization in the Era of Immuno-Oncology
George D. Demetri, MD - The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond
January 25, 2019 23:00 - 1 hourThe Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond
Jorge A. Marrero, MD, MS - Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes
January 11, 2019 23:00 - 1 hourSurveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes
Steven Brem, MD - Transforming Glioblastoma Management: A MasterClass on Evaluating Newer and Emerging Options in the Precision Medicine and Person-Centered Care Era
January 09, 2019 23:00 - 54 minutesTransforming Glioblastoma Management: A MasterClass on Evaluating Newer and Emerging Options in the Precision Medicine and Person-Centered Care Era
Andre H. Goy, MD - Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management
January 07, 2019 23:00 - 1 hourExploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management
Roy H. Decker, MD, PhD - The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal
December 28, 2018 23:00 - 58 minutesThe Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal
Lynette M. Sholl, MD - Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do
December 19, 2018 23:00 - 1 hourMolecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do
Amir T. Fathi, MD - The Oncologist, Nurse, and Patient Partnership in AML: Multiple Perspectives on Integrating Targeted Therapy Into Care
December 17, 2018 23:00 - 42 minutesThe Oncologist, Nurse, and Patient Partnership in AML: Multiple Perspectives on Integrating Targeted Therapy Into Care
Kurt Schalper, MD, PhD and Edward B. Garon, MD, MS - Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution
December 14, 2018 23:00 - 52 minutesAdvances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution
Anjali Saqi, MD, MBA and Geoffrey R. Oxnard, MD - Navigating the Complexities of Molecular Testing for EGFR Mutations to Guide Treatment Selection in Lung Cancer: Evidence, Practicalities, and Implications for Pathologists
December 07, 2018 23:00 - 48 minutesNavigating the Complexities of Molecular Testing for EGFR Mutations to Guide Treatment Selection in Lung Cancer: Evidence, Practicalities, and Implications for Pathologists
Edward B. Garon, MD, MS - Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice
December 03, 2018 23:00 - 1 hourImproving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice
Daniel Pallin, MD, MPH - Emergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Cancer Immunotherapy–Related Adverse Effects in the Emergency Department
November 30, 2018 23:00 - 1 hourEmergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Cancer Immunotherapy–Related Adverse Effects in the Emergency Department
Mark T. Reding, MD - Treatment Innovation in hemophilia A: Integrating Extended Half-Life Replacement Clotting Factors Into Clinical Practice
November 12, 2018 23:00 - 38 minutesTreatment Innovation in hemophilia A: Integrating Extended Half-Life Replacement Clotting Factors Into Clinical Practice
Michael Wang, MD - Integrating BTK Inhibitors Into the Management of B-Cell Malignancies: How Is Evidence Driving Patient Care?
October 22, 2018 23:00 - 38 minutesIntegrating BTK Inhibitors Into the Management of B-Cell Malignancies: How Is Evidence Driving Patient Care?
Nathan H. Fowler, MD - Innovative Therapy in B-Cell Malignancies: An Expert Tumor Board on Novel Agent Classes in CLL, FL, and MCL
October 17, 2018 23:00 - 1 hourInnovative Therapy in B-Cell Malignancies: An Expert Tumor Board on Novel Agent Classes in CLL, FL, and MCL
Unraveling the Complex Treatment Landscape of Prostate Cancer: Guidance for Delivering Evidence-Based, Patient-Centered Care
October 15, 2018 23:00 - 44 minutesUnraveling the Complex Treatment Landscape of Prostate Cancer: Guidance for Delivering Evidence-Based, Patient-Centered Care